DOCSLIB.ORG

First Evidence of the Conversion of Paracetamol to AM404 in Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
First Evidence of the Conversion of Paracetamol to AM404 in Human Journal of Pain Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH First evidence of the conversion of paracetamol WR$0LQKXPDQFHUHEURVSLQDOÁXLG This article was published in the following Dove Press journal: Journal of Pain Research Chhaya V Sharma,1 Jamie H Abstract: Paracetamol is arguably the most commonly used analgesic and antipyretic drug Long,2 Seema Shah,1 Junia worldwide, however its mechanism of action is still not fully established. It has been shown to Rahman,1 David Perrett,3 exert effects through multiple pathways, some actions suggested to be mediated via N-arachi- Samir S Ayoub,4 Vivek donoylphenolamine (AM404). AM404, formed through conjugation of paracetamol-derived Mehta1 p-aminophenol with arachidonic acid in the brain, is an activator of the capsaicin receptor, TRPV1, and inhibits the reuptake of the endocannabinoid, anandamide, into postsynaptic neurons, 1Pain & Anaesthesia Research Centre, as well as inhibiting synthesis of PGE by COX-2. However, the presence of AM404 in the cen- St Bartholomew’s and The Royal 2 London Hospitals, Barts Health NHS tral nervous system following administration of paracetamol has not yet been demonstrated in Trust, London, UK; 2Barts & The humans. Cerebrospinal fluid (CSF) and blood were collected from 26 adult male patients between London School of Medicine, Queen Mary University of London, London, 10 and 211 minutes following intravenous administration of 1 g of paracetamol. Paracetamol UK; 3BioAnalytical Science, Barts & was measured by high-performance liquid chromatography with UV detection. AM404 was The London School of Medicine, measured by liquid chromatography-tandem mass spectrometry. AM404 was detected in 17 of Queen Mary University of London, – London, UK; 4School of Health, Sport the 26 evaluable CSF samples at 5–40 nmol⋅L 1. Paracetamol was measurable in CSF within 10 and Bioscience, Medicines Research minutes, with a maximum measured concentration of 60 μmol⋅L–1 at 206 minutes. This study is Group, University of East London, London, UK the first to report on the presence of AM404 in human CSF following paracetamol administra- tion. This may represent an important finding in our understanding of paracetamol’s mechanism of action, although measured concentrations were far below the previously documented IC50 Video abstract for this metabolite. Keywords: acetaminophen, paracetamol, paracetamol: mechanism of action, AM404, N- arachidonoylphenolamine, pharmacology - theories of analgesic action Introduction Despite its discovery over a century ago and ubiquitous clinical use, the mechanism of action of paracetamol remains undetermined, although involvement of multiple central pathways has been demonstrated. These include effects on prostaglandin production,1,2 on serotonergic pathways,3,4 and more recently, there has been increasing evidence for the roles of the endocannabinoid system and TRPV1 receptor in paracetamol’s Point your SmartPhone at the code above. If you have a antinociceptive (though not its hypothermic) effects.5–8 QR code reader the video abstract will appear. Or use: http://youtu.be/0umrSpQgoeU Arachidonoyl ethanolamine (AEA, anandamide) is an endogenous cannabinoid present in the human nervous system, with demonstrated antinociceptive actions. Its actions are terminated by a two-step inactivation process beginning with its reup- Correspondence: Chhaya V Sharma take from the synaptic cleft into the postsynaptic neuron by a recently characterized Department of Anaesthesia, 4th Floor, FAAH-like anandamide transporter (FLAT).9 Inside the neuron, AEA is hydrolyzed North Tower, Royal London Hospital, by the enzyme FAAH. Paracetamol has been suggested to exert its analgesic actions Whitechapel, E1 1BB, London, UK Email [email protected] by interfering with the reuptake of AEA by using FAAH to form a novel metabolite submit your manuscript | www.dovepress.com Journal of Pain Research 2017:10 2703–2709 2703 Dovepress © 2017 Sharma et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. http://dx.doi.org/10.2147/JPR.S143500 php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Sharma et al Dovepress N-arachidonoylphenolamine (AM404) through conjugation Sample collection and storage in brain tissue of paracetamol-derived para-aminophenol with CSF and blood sample were collected into EDTA tubes, arachidonic acid.10 The consequence of this is increased AEA stored on ice, centrifuged at 1,400× g at 4°C for 15 minutes, within the synaptic cleft, producing increased cannabinoid and then frozen at -20°C until analysis. 10,11 receptor (CB1) activation. AM404 is also an activator of TRPV1, otherwise known as the capsaicin receptor.7,10 Materials Although the potential central antinociceptive role of Paracetamol reference samples were from Sigma-Aldrich Co. AM404 has been investigated in animal models, its role (St Louis, MO, USA); AM404 and palmitoylethanolamide- in humans is not clear. AM404 has been found only as a d4 (PEA-d4) were from Cayman Chemicals (Ann Arbor, metabolite of paracetamol and is not an endogenous com- MI, USA); ammonium acetate, potassium phosphate, and ponent of human or animal nervous systems.7,12 However, its EDTA were from VWR (Lutterworth, UK). Analytical grade presence in cerebrospinal fluid (CSF) following paracetamol methanol, acetonitrile, H2O, and formic acid were from Fisher administration in humans has not been reported. The purpose Scientific UK Ltd (Loughborough, UK). of this pilot study was to investigate whether AM404 is present in human CSF following a single intravenous dose Measurement of paracetamol in CSF and of paracetamol. plasma High-performance liquid chromatography (HPLC) analysis Methods was performed on a Jasco system. CSF (100 μL) was diluted Study design and patient randomization with 100 μL 50 mM ammonium acetate, pH 5.5, containing Following approval by the East London Research Ethics 183 mmol.mL–1 3-aminophenol (internal standard). One Committee (ref: 2010-019488-12), EudraCT registration (ref: hundred microliters of plasma was precipitated with 300 μL 2010-019488-12), and receipt of written informed consent acetonitrile containing 183 mmol.mL–1 3-aminophenol. from all participants, 30 American Society of Anesthesiology Extracted plasma was centrifuged at 13,000× g for 10 min- classification of perioperative risk of anesthesia I–III adult utes and 100 μL supernatant was diluted with 100 μL 50 mM male and female patients, aged between 18 and 80 years, potassium phosphate, pH 6.5. Extracts were injected (20 μL were recruited to the study. These patients were scheduled for CSF, 10 μL for plasma) and separated on a Thermo Sci- to undergo elective urological surgery under spinal anesthe- entific C18 column (100 × 4.6 mm, 5 μm). For CSF, elution sia. Exclusion criteria were any contraindication to spinal was carried out with 50 mM ammonium acetate (pH 5.5) con- anesthesia, known hypersensitivity to paracetamol or severe taining 1 mM EDTA and 5% methanol. For plasma, 50 mM hepatocellular insufficiency, patients taking paracetamol potassium phosphate (pH 6.5) containing 1 mM EDTA and in the preceding 12 hours, or pregnancy or lactation in 5% methanol was used. The column was eluted at 1 mL.min–1 women. Patients were given a single intravenous dose of 1 using a Jasco PU-980 pump. Detection was at 242 nm using g paracetamol (100 mL solution, Perfalgan; Bristol-Myers a Jasco UV-975 detector. The retention time for paracetamol Squibb Pharmaceutical Limited, Middlesex, UK) as an was 7.05 minutes and that of the internal standard was infusion over 10 minutes, and were randomized for sample 3.5 minutes. The HPLC for paracetamol was calibrated to a collection at 15, 30, or 120 minutes post-infusion, prior to six-point curve of 0–1.65 mmol⋅L–1. The matrix was PBS for their spinal anesthetic (administration to sampling interval). CSF and paracetamol-free human plasma for plasma samples. At the time of the lumbar puncture but before injection of The limit of detection for paracetamol in CSF and plasma intrathecal local anesthetic agents, CSF (5 mL) and blood were 54 nmol⋅L–1 and 200 nmol⋅L–1, respectively (S/N=3). (10 mL) samples were collected. The limits of quantitation for paracetamol in CSF and plasma Randomization was achieved using sealed envelopes were 180 nmol⋅L–1 and 600 nmol⋅L–1, respectively (S/N=10). containing the study group allocation (for sampling at 15, 30, or 120 minutes post-paracetamol administration). The sealed Measurement of AM404 in CSF and envelope was selected by a member of the research team not plasma involved in data collection or analysis.13 As outcomes of the Liquid chromatography-tandem mass spectrometry (LC- study were measured values of paracetamol and its metabo- MS/MS) analysis was performed on a Thermo Scientific lite, AM404, rather than subjective patient experience, clini- Accela system attached to a TSQ Vantage mass spectrom- cal bias was not a concern and masking was not carried out. eter. One hundred microliters of CSF was diluted with 2704 submit your manuscript | www.dovepress.com Journal of Pain Research 2017:10 Dovepress Dovepress Paracetamol metabolism to AM404 in human CSF 100 μL H2O. One hundred microliters of plasma was pre- set as follows: collision gas was argon, spray voltage was cipitated with 300 μL acetonitrile containing 329 nmol/L 3,500 V, vaporizer temperature was 300°C, sheath gas pres- internal standard PEA-d4. Extracts (10 μL) were injected sure was 60 psi, capillary temperature was 270°C, collision onto a Waters Acquity BEH phenyl column (2.1 × 50 mm, cell pressure was 1.5 mTorr, and no declustering voltage 1.7 μm), maintained at 50°C, and eluted at 0.5 mL⋅min–1.
Load more

Recommended publications
  • Issue 3 Combinations Were Banned in the Month of March, 2016
    344 FDC’s REGIMEN Banned in CHIPS India The Health Ministry has banned 344 ‘Fixed HIP C S ✪ Dose Combination’ (FDC) ✪ drugs, leading to an immediate suspension of the manufacturing and sale of some popular medicines in India. Fixed drug combinations have mushroomed in the market as the Pharmaceutical companies ✪ in their quest for newer products and to increase G ✪ UNTUR FR Drug Information News Letter its sales, mix and match ingredients into a single OM C EATION molecule to market them as newer remedies. 344 of such ONCEPT TO CR Jan-Mar 2016, Volume 1, Issue 3 combinations were banned in the month of March, 2016. Keeping in view of the Risk that is associated with these Fixed drug combinations and safer alternatives being available in the market, the Ministry moved ahead with its decision to ban all the 344 fixed drug combinations. Simethicone, *fixed dose combination of Magaldrate + Papain + Fungul Here is the list of 344 banned fixed Drug Combinations in India Diastase + Simethicone, *fixed dose combination of Rabeprazole + Zinc + Domperidone, *fixed dose combination of Famotidine + Oxytacaine + *Aceclofenac + Paracetamol + Rabeprazole, *Nimesulide + Diclofenac, *Diphenoxylate + Atropine + Furazolidone, * Combikit of Fluconazole Magaldrate,*fixed dose combination of Ranitidine + Domperidone + *Nimesulide + Cetirizine + Caffeine, *Nimesulide + Tizanidine, Tablet, Azithromycin Tablet and Ornidazole Tablets, *Ciprofloxacin + Simethicone,*fixed dose combination of Alginic Acid + Sodium *Paracetamol + Cetirizine + Caffeine*Diclofenac +
    [Show full text]
  • Ascorbic Acid/ Paracetamol/ Phenylephrine Hydrochloride PSUSA/00000255/202006 List of Nationally Authorised Medicinal Products
    11 February 2011 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance: ascorbic acid/paracetamol/phenylephrine hydrochloride Procedure no.: PSUSA/00000255/202006 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Member State where Product full name MRP/DCP or CP National Authorisation MAH of product in the member product is (in authorisation country) Authorisation number Number state authorised OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/06 KFT. HU OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/05 KFT. HU OMEGA PHARMA HUNGARY Coldrex méz és citrom ízű por belsőleges oldathoz not available OGYI-T-1715/11 KFT. HU Blackcurrant Coldrex Powders not available PL 02855/0271 OMEGA PHARMA LTD UK AZIENDE CHIMICHE RIUNITE TACHIFLUDEC polvere per soluzione orale gusto ANGELINI FRANCESCO - menta not available 034358073 A.C.R.A.F. S.P.A. IT AZIENDE CHIMICHE RIUNITE TACHIFLUDEC polvere per soluzione orale gusto ANGELINI FRANCESCO - menta. not available 034358085 A.C.R.A.F. S.P.A. IT List of nationally authorised medicinal products Page 2/8 COLDREX MAXGRIP MENTHOL & BERRIES, 1000 mg/70 mg/10 mg, suukaudse lahuse pulber kotikeses not available 798812 RICHARD BITTNER AG, EE GLAXOSMITHKLINE CONSUMER HEALTHCARE Beechams Cold & Flu Hot Lemon not available MA 932/00103 (UK) TRADING LIMITED MT OMEGA PHARMA HUNGARY Coldrex citrom ízű por belsőleges oldathoz not available OGYI-T-1715/01 KFT.
    [Show full text]
  • Management of Poisoning
    MOH CLINICAL PRACTICE GUIDELINES December/2011 Management of Poisoning Health Ministry of Sciences Chapter of Emergency College of College of Family Manpower Authority Physicians Physicians, Physicians Academy of Medicine, Singapore Singapore Singapore Singapore Medical Pharmaceutical Society Society for Emergency Toxicology Singapore Paediatric Association of Singapore Medicine in Singapore Society (Singapore) Society Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Principles of management of acute poisoning – resuscitating the poisoned patient GPP In a critically poisoned patient, measures beyond standard resuscitative protocol like those listed above need to be implemented and a specialist experienced in poisoning management should be consulted (pg 55). GPP D Prolonged resuscitation should be attempted in drug-induced cardiac arrest (pg 55). Grade D, Level 3 1 C Titrated doses of naloxone, together with bag-valve-mask ventilation, should be administered for suspected opioid-induced coma, prior to intubation for respiratory insuffi ciency (pg 56). Grade C, Level 2+ D In bradycardia due to calcium channel or beta-blocker toxicity that is refractory to conventional vasopressor therapy, intravenous calcium, glucagon or insulin should be used (pg 57). Grade D, Level 3 B Patients with actual or potential life threatening cardiac arrhythmia, hyperkalaemia or rapidly progressive toxicity from digoxin poisoning should be treated with digoxin-specifi c antibodies (pg 57). Grade B, Level 2++ B Titrated doses of benzodiazepine should be given in hyperadrenergic- induced tachycardia states resulting from poisoning (pg 57). Grade B, Level 1+ D Non-selective beta-blockers, like propranolol, should be avoided in stimulant toxicity as unopposed alpha agonism may worsen accompanying hypertension (pg 57).
    [Show full text]
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • 1. Generic Name Paracetamol, Phenylephrine, Chlorpheniramine Maleate, Sodium Citrate, Menthol 2. Qualitative and Quantitative Co
    1. Generic Name Paracetamol, Phenylephrine, Chlorpheniramine maleate, Sodium citrate, Menthol 2. Qualitative and Quantitative composition Paracetamol 125 mg Phenylephrine 5 mg Chlorpheniramine maleate 1 mg Sodium citrate 60 mg Mentholated flavoured syrupy base q.s. 3. Dosage form and strength Oral syrup containing Paracetamol 125 mg, Phenylephrine 5 mg, Chlorpheniramine maleate 1 mg. 4. Clinical particulars 4.1 Therapeutic indication Sinarest Syrup is indicated in children below 40 kg weight for: • Relief of nasal and sinus congestion. • Relief of allergic symptoms of the nose or throat due to upper respiratory tract allergies. • Relief of sinus pain and headache. • Adjunct with antibacterial in sinusitis, tonsillitis and otitis media. 4.2 Posology and method of administration Children of age between 2 to 12 years (body weight- 6 - 40 kg): The usual recommended dose is as shown in the table below which will be given to the patient: Weight Age Dose 6 – 22.9 2 – 7 years 5 ml BID 11.9 – 40 7 – 12 years 5 ml TID 4.3 Contraindication The use of Sinarest syrup is contraindicated in patients with: Hypersensitivity to any of the ingredients of the formulation. Severe hypertension. 4.4 Special warnings and precautions for use In case a hypersensitivity reaction occurs which is rare, Sinarest syrup should be discontinued. Sinarest syrup contains Paracetamol and therefore should not be used in conjunction with other Paracetamol containing products. Sinarest syrup should be used with caution in patients with renal or hepatic dysfunction, diabetes mellitus, hyperthyroidism, cardiovascular problems, epilepsy and closed angle glaucoma. 4.5 Drug interactions Clinically significant drug interactions may occur on concomitant administration of Sinarest syrup with monoamine oxidase inhibitors, tricyclic antidepressants, beta-adrenergic agents, and methyldopa, reserpine and veratrum alkaloids.
    [Show full text]
  • Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: a Systematic Review of Human and Animal Evidence
    nutrients Review Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence Marco Colizzi 1,2,3,* , Riccardo Bortoletto 1, Rosalia Costa 4 and Leonardo Zoccante 1 1 Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, 37126 Verona, Italy; [email protected] (R.B.); [email protected] (L.Z.) 2 Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy 3 Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, UK 4 Community Mental Health Team, Department of Mental Health, ASST Mantova, 46100 Mantua, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-045-812-6832 Abstract: Autism spectrum disorder (ASD) pathophysiology is not completely understood; how- ever, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment. Palmi- toylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective in controlling inflammation, depression, epilepsy, and pain, possibly through a neuro- Citation: Colizzi, M.; Bortoletto, R.; protective role against glutamate toxicity. Here, we systematically reviewed all human and animal Costa, R.; Zoccante, L. studies examining PEA and its biobehavioral correlates in ASD. Studies indicate altered serum/brain Palmitoylethanolamide and Its levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD. Altered PEA Biobehavioral Correlates in Autism signaling response to social exposure and altered expression/activity of enzymes responsible for Spectrum Disorder: A Systematic the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator Review of Human and Animal α α Evidence.
    [Show full text]
  • Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’S Disease
    Molecular Neurobiology https://doi.org/10.1007/s12035-019-1637-8 Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease David Schubert1 & Devin Kepchia1 & Zhibin Liang1 & Richard Dargusch1 & Joshua Goldberg & Pamela Maher1 Received: 30 January 2019 /Accepted: 6 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Finding a therapy for Alzheimer’s disease (AD) is perhaps the greatest challenge for modern medicine. The chemical scaffolds of many drugs in the clinic today are based upon natural products from plants, yet Cannabis has not been extensively examined as a source of potential AD drug candidates. Here, we determine if a number of non-psychoactive cannabinoids are neuroprotective in a novel pre-clinical AD and neurodegeneration drug-screening platform that is based upon toxicities associated with the aging brain. This drug discovery paradigm has yielded several compounds in or approaching clinical trials for AD. Eleven cannabinoids were assayed for neuroprotection in assays that recapitulate proteotoxicity, loss of trophic support, oxidative stress, energy loss, and inflammation. These compounds were also assayed for their ability to remove intraneuronal amyloid and subjected to a structure-activity relationship analysis. Pairwise combinations were assayed for their ability to synergize to produce neuropro- tective effects that were greater than additive. Nine of the 11 cannabinoids have the ability to protect cells in four distinct phenotypic neurodegeneration screening assays, including those using neurons that lack CB1 and CB2 receptors. They are able to remove intraneuronal Aβ, reduce oxidative damage, and protect from the loss of energy or trophic support.
    [Show full text]
  • Risk Perception of Medicinal Marijuana in Medical Students from Northeast Mexico[Version 1; Referees: Awaiting Peer Review]
    F1000Research 2017, 6:1802 Last updated: 04 OCT 2017 RESEARCH ARTICLE Risk perception of medicinal marijuana in medical students from northeast Mexico [version 1; referees: awaiting peer review] Sandra Castillo-Guzmán1, Dionicio Palacios-Ríos1, Teresa A. Nava-Obregón1, Julio C. Arredondo-Mendoza1, Olga V. Alcalá-Alvarado1, Sofía A. Alonso-Bracho1, Daniela A. Becerril-Gaitán1, Omar González-Santiago 2 1Pain and Palliative Care Clinic, Anesthesiology Service, Hospital Universitario Dr. José E. González y Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico 2Postgraduate in Pharmacy, Faculty of Chemical Science, Universidad Autónoma de Nuevo León, San Nicolas de Los Garza, Nuevo León, Mexico v1 First published: 04 Oct 2017, 6:1802 (doi: 10.12688/f1000research.12638.1) Open Peer Review Latest published: 04 Oct 2017, 6:1802 (doi: 10.12688/f1000research.12638.1) Referee Status: AWAITING PEER Abstract Background. Several studies have shown support from the public toward the REVIEW use of medicinal marijuana. In this cross-sectional study, we assess the risk perception to medicinal marijuana in a sample of medical students. Discuss this article Methods. To estimate risk perception, a visual scale that ranges from 0 cm Comments (0) (without risk) to 10 cm (totally risky) was used. Risk perception was expressed as the median of the cm marked over the scale. Differences among groups was tested with the Mann-Whitney and Kruskal-Wallis tests, as appropriate. Results. 283 students participated in the study. Risk perception to medicinal marijuana was 4.22, paracetamol 1.56 and sedatives 5.0. A significant difference in risk perception was observed in those that self-reported to smoke and consume alcohol.
    [Show full text]
  • Perception of the Risk of Medicinal Marijuana in Postgraduate Medical Residents[Version 1; Peer Review: Awaiting Peer Review]
    F1000Research 2019, 8:381 Last updated: 14 MAY 2021 RESEARCH NOTE Perception of the risk of medicinal marijuana in postgraduate medical residents [version 1; peer review: awaiting peer review] Sandra Castillo-Guzmán , Dionicio Palacios Ríos, Teresa Adriana Nava Obregón, Daniela Alejandra Becerril Gaitàn, Keren Daniela Juangorena García, Danya Carolina Domínguez Romero, Misael Jerónimo Reyes Rodríguez Pain and Palliative Care Clinic, Anesthesiology Service, Hospital Universitario Dr.Jose Eleuterio González y Facultad de Medicina de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, 66463, Mexico v1 First published: 04 Apr 2019, 8:381 Open Peer Review https://doi.org/10.12688/f1000research.17394.1 Latest published: 04 Apr 2019, 8:381 https://doi.org/10.12688/f1000research.17394.1 Reviewer Status AWAITING PEER REVIEW Any reports and responses or comments on the Abstract article can be found at the end of the article. Background: Drugs can often cause adverse reactions, and the perception of the risk of prescription drugs could influence prescription behaviour. Methods: This was a prospective cross-sectional study of the perception of postgraduate physicians in training of the risk of using medical marijuana, comparing it with their perception of paracetamol and sedatives. A visual analogue scale with ranges from 0 (no risk) to 10 (totally risky) was used. Results: A total of 197 postgraduate students were evaluated; 48 women and 149 men took part, with a mean age 27.8 years. Among the different specialties, there was a difference with regard to the perception of medical marijuana and paracetamol and all perceived a greater risk with sedatives. There was no evidence of a risk perception of marijuana in relation to factors such as alcohol consumption and smoking.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    PROTOCOL: Cannabidiol for Fibromyalgia AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital DATE: 2020-12-14 Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov Identifier: CLINICAL TRIAL PROTOCOL Cannabidiol for Fibromyalgia The CANNFIB trial Protocol for a randomized, double-blind, placebo-controlled, parallel-group, single-center trial Sponsor Investigator Marianne Uggen Rasmussen (MUR) RN, MPH, PhD; Post-doctoral fellow Primary Investigator and Supervisor Kirstine Amris (KA) MD, DMSc; Senior Rheumatologist CO-investigator and statistical advisor Robin Christensen (RC) MSc, PhD; Professor of Biostatistics and Clinical Epidemiology CO-investigator and advisor Eva Ejlersen Wæhrens (EEW) OT, DMSc; Senior Researcher CO-investigator and advisor Henning Bliddal (HB) MD, DMSc; Professor of Rheumatology Sponsor contact details Marianne Uggen Rasmussen The Parker Institute, Bispebjerg and Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg Phone: +45 38164197 Email: [email protected] 0 PROTOCOL: Cannabidiol for Fibromyalgia AUTHOR: Marianne Uggen Rasmussen, The Parker Institute, Copenhagen University Hospital DATE: 2020-12-14 Protocol number P142; Version: 4; EudraCT: 2019-002394-59, Regional Ethical Committee Journal Number H-20047715. ClinicalTrials.gov Identifier: LIST OF ABBREVIATIONS ACR American college of rheumatology ADL-Q Activities of daily living questionnaire AE Adverse events AMPS Assessment
    [Show full text]
  • Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious?
    molecules Review Endocannabinoid System Dysregulation from Acetaminophen Use May Lead to Autism Spectrum Disorder: Could Cannabinoid Treatment Be Efficacious? Stephen Schultz 1, Georgianna G. Gould 1, Nicola Antonucci 2, Anna Lisa Brigida 3 and Dario Siniscalco 4,* 1 Department of Cellular and Integrative Physiology, Center for Biomedical Neuroscience, University of Texas (UT) Health Science Center San Antonio, San Antonio, TX 78229, USA; [email protected] (S.S.); [email protected] (G.G.G.) 2 Biomedical Centre for Autism Research and Therapy, 70126 Bari, Italy; [email protected] 3 Department of Precision Medicine, University of Campania, 80138 Naples, Italy; [email protected] 4 Department of Experimental Medicine, University of Campania, 80138 Naples, Italy * Correspondence: [email protected] Abstract: Persistent deficits in social communication and interaction, and restricted, repetitive pat- terns of behavior, interests or activities, are the core items characterizing autism spectrum disorder (ASD). Strong inflammation states have been reported to be associated with ASD. The endocannabi- noid system (ECS) may be involved in ASD pathophysiology. This complex network of lipid signal- ing pathways comprises arachidonic acid and 2-arachidonoyl glycerol-derived compounds, their G-protein-coupled receptors (cannabinoid receptors CB1 and CB2) and the associated enzymes. Alter- Citation: Schultz, S.; Gould, G.G.; ations of the ECS have been reported in both the brain and the immune system of ASD subjects. ASD Antonucci, N.; Brigida, A.L.; Siniscalco, D. Endocannabinoid children show low EC tone as indicated by low blood levels of endocannabinoids. Acetaminophen System Dysregulation from use has been reported to be associated with an increased risk of ASD.
    [Show full text]
  • Grunddokument 2
    The cellular processing of the endocannabinoid anandamide and its pharmacological manipulation Lina Thors Department of Pharmacology and Clinical Neuroscience SE-901 87 Umeå, Sweden Umeå 2009 1 Copyright©Lina Thors ISBN: 978-91-7264-732-9 ISSN: 0346-6612 Printed by: Print & Media Umeå, Sweden 2009 2 Abstract Anandamide (arachidonoyl ethanolamide, AEA) and 2-arachidonoyl glycerol (2-AG) exert most of their actions by binding to cannabinoid receptors. The effects of the endocannabinoids are short-lived due to rapid cellular accumulation and metabolism, for AEA, primarily by the enzymes fatty acid amide hydrolase (FAAH). This has led to the hypothesis that by inhibition of the cellular processing of AEA, beneficial effects in conditions such as pain and inflammation can be enhanced. The overall aim of the present thesis has been to examine the mechanisms involved in the cellular processing of AEA and how they can be influenced pharmacologically by both synthetic natural compounds. Liposomes, artificial membranes, were used in paper I to study the membrane retention of AEA. The AEA retention mimicked the early properties of AEA accumulation, such as temperature- dependency and saturability. In paper II, FAAH was blocked by a selective inhibitor, URB597, and reduced the accumulation of AEA into RBL2H3 basophilic leukaemia cells by approximately half. Treating intact cells with the tyrosine kinase inhibitor genistein, an isoflavone found in soy plants and known to disrupt caveolae-related endocytosis, reduced the AEA accumulation by half, but in combination with URB597 no further decrease was seen. Further on, the effects of genistein upon uptake were secondary to inhibition of FAAH.
    [Show full text]